Drug discovery company focused on developing pharmaceutical products targeting G-protein coupled receptors (GPCRs).
At Trevena, our mission is to deliver innovative solutions to patients and healthcare providers confronting serious medical conditions.
- Founded in 2007
- Publicly Traded (NASDAQ: TRVN)
- Headquarters: King of Prussia, PA
Our lead product candidate is oliceridine (TRV130), an innovative new chemical entity currently in Phase 3 clinical trials for the management of moderate-to-severe acute pain. Based on the results of our earlier clinical trials, oliceridine was designated a Breakthrough Therapy by the U.S. Food and Drug Administration. We also have discovered several other product candidates with the potential to address problems across a wide range of therapeutic areas, including moderate-to-severe acute and chronic pain, and acute episodic migraine. In addition, we have an early-stage portfolio of drug discovery programs currently in lead optimization.
Our history is rooted in strong science – Trevena was founded to translate Nobel Prize-winning research into a new generation of groundbreaking medicines. Our novel approach to drug discovery has established us as pioneers in acute care medicine.